Policy Issue Briefs: BARDA and ARPA-H
These two policy briefs explore two as yet untapped sources for drug-resistant tuberculosis (DR-TB) research funding within the U.S. Department of Health and Human Services (HHS).
TPT Community Materials
These free educational materials are designed for community-based and civil society organizations to use to advocate for and teach people about TB preventive treatment (TPT).
Statement from TAG, Global TB CAB on H56:IC31 Phase IIb Trial Results
This week, the Statens Serum Institut (SSI) and IAVI shared topline results of the phase IIb trial of H56:IC31, a subunit TB vaccine developed by SSI in Denmark consisting of four Mycobacterium tuberculosis antigens and the IC31 adjuvant made by Valneva.
Report: TB R&D Funding Perilously Off Track of UN Commitments to End Disease by 2030
A new report released today by Treatment Action Group (TAG) and the Stop TB Partnership has found that cumulative funding for tuberculosis (TB) research and development (R&D) over the past five years is falling shockingly short of commitments.
An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis
An updated, version of this publication was released in 2025. In 2022, the World Health Organization (WHO) updated its guidelines for treating drug-resistant tuberculosis (DR-TB), recommending a six-month cure. This guide lays out what activists need to know about the…
ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.
TAG Condemns GSK Actions Surrounding Potential TB Vaccine Revealed by Bombshell ProPublica Report
TAG is appalled by the revelations set forth in Anna Marie Barry-Jester’s deeply reported investigation for ProPublica, “How a Big Pharma Company Stalled a Potentially Lifesaving Vaccine in Pursuit of Bigger Profits,” published online October 4.
Beyond Intellectual Property: Why Is Generic Treatment for HCV Still So Hard to Get
By Joelle Dountio Ofimboudem and Sara Helena Gaspar Background Intellectual property is a major barrier to access to medicines worldwide because it creates corporate monopolies that restrict supply, keep prices high, and prevent people from accessing innovative health products. However,…
Misinformation and Vaccine Preparedness: The Case for Digital Advocacy
By Erin McConnell A special thanks to Abraham Johnson, for contributing to an earlier draft of this piece Hesitancy around immunization has such deep historical roots that it predates the first vaccine. Before the term “anti-vaccine” was coined in the…
How Rising Anti-LGBTQ Sentiment Harms Public Health
By Kendall Martinez-Wright, Elizabeth Lovinger, and De’Ashia Lee Many people recognize advances the LGBTQ+ community has made in the United States and other countries, including the freedom to marry their partners, sexual orientation and gender identity protections, and the fact…